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Intermediate syndrome (IMS) is a major cause of death from respiratory failure following
acute organophosphate poisoning. The objective of this study was to determine repetitive
nerve stimulation (RNS) predictors of IMS that would assist in patient management and clinical
research.
Methods and Findings
Seventy-eight consenting symptomatic patients with organophosphate poisoning were
assessed prospectively with daily physical examination and RNS. RNS was done on the right
and left median and ulnar nerves at 1, 3, 10, 15, 20, and 30 Hz. The study was conducted as a
prospective observational cohort study in the Central Province, Sri Lanka. IMS was diagnosed in
ten out of 78 patients using a priori clinical diagnostic criteria, and five of them developed
respiratory failure. All ten patients showed progressive RNS changes correlating with the
severity of IMS. A decrement-increment was observed at intermediate and high frequencies
preceding the onset of clinical signs of IMS. As the patient developed clinical signs of IMS,
decrement-increment was progressively noted at low and intermediate frequencies and a
combination of decrement-increment and repetitive fade or severe decrement was noted at
high frequencies. Severe decrement preceded respiratory failure in four patients. Thirty patients
developed forme fruste IMS with less severe weakness not progressing to respiratory failure
whose RNS was characterized by decrement-increment or a combination of decrement-
increment and repetitive fade but never severe decrements.
Conclusions
Characteristic changes in RNS, preceding the development of IMS, help to identify a
subgroup of patients at high risk of developing respiratory failure. The forme fruste IMS with the
characteristic early changes on RNS indicates that IMS is a spectrum disorder. RNS changes are
objective and precede the diagnosis and complications of IMS. Thus they may be useful in
clinical management and research.
The Editors’ Summary of this article follows the references.
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Organophosphate (OP) poisoning is a major global health
problem [1,2] with hundreds of thousands of deaths every
year [3,4]. OP poisoning leads to three main syndromes: (1)
acute cholinergic syndrome, (2) intermediate syndrome (IMS),
and (3) OP-induced delayed polyneuropathy (OPIDPN). IMS
remains a major contributor to the high morbidity and
mortality in OP poisoning, an important and expensive
medical problem in the under-resourced developing world
[5].
IMS was ﬁrst described [5] as a syndrome of muscular
paralysis occurring in conscious patients 24–96 h following
ingestion, after their acute cholinergic syndrome was treated
with atropine. Muscle weakness affected predominantly the
proximal limb muscles and those supplied by the cranial
nerves. IMS was often associated with respiratory failure.
More recent work suggest that IMS could occur before 24 h
and even after 96 h [6–8]. The pathophysiology of IMS is not
clearly understood [8–15] but is generally believed to result
from a persistent excess of acetylcholine (ACh) at the
neuromuscular junction [8,11,13,14,16–21].
Neuromuscular transmission has been recorded in OP
poisoning in general and in patients with IMS using repetitive
nerve stimulation (RNS) and single ﬁber electromyography
[8,22–27]. Neuromuscular transmission failure induced by
OPs and other anticholinesterases (e.g., neostigmine) has
been extensively studied in animals especially in rat models
[23,28–32]. However there are no previous studies to our
knowledge that have evaluated patients with serial RNS from
the onset of poisoning to describe sequential electrophysio-
logical changes that correlate with clinical severity in IMS.
The objective of this study was to serially assess the neuro-
muscular junctional function with RNS in patients who are at
risk of developing IMS to gather more information on the
pathophysiology, and to determine any predictors of the
syndrome that would be relevant clinically and in research.
Methods
A prospective observational study of symptomatic OP
poisoned patients was carried out in the Central Province of
Sri Lanka with the approval of the Ethics Committees of the
University of Peradeniya, Sri Lanka and the Australian
National University, Canberra, Australia. Patients were
recruited from Nuwara Eliya General Hospital, Nuwara Eliya
from May 2005 to April 2005 and from Teaching Hospital,
Peradeniya from May 2006 to December 2006.
All patients were assessed on admission and repeatedly
thereafter for features of acute cholinergic syndrome. The
inclusion criteria were admission within 24 h of ingestion of
OP and signs of systemic intoxication. Patients ,15 y of age
and pregnant patients were excluded. Informed written
consent was obtained from all the study patients. When it
was initially not possible to get consent from the patients
(e.g., when they were unconscious), consent was obtained
from the accompanying relatives but this was later conﬁrmed
from the patients themselves when they regained conscious-
ness and were orientated and rational.
OP poisoning was conﬁrmed by the history from the
patient and/or relatives, containers brought to hospital,
records in patient-transfer forms, characteristic smell in the
breath, and clinical features typical of OP poisoning. OP
concentration in plasma was quantiﬁed in 67 of 78 patients
using reversed phase high performance liquid chromatog-
raphy and ultraviolet detection [33]. Red blood cell acetyl-
cholinesterase (RBC AChE) level was assessed in 59 of 78
patients using modiﬁed Elman method [34]. Accordingly,
additional biochemical evidence of OP poisoning (serum OP
level or RBC AChE level) was available in 69 of the 78
patients.
As per institutional practices patients were treated with
10–15 mg bolus dose of atropine followed by 10–15 mg IV
atropine infusion in 0.9% normal saline over about 12 h. The
infusion rate was adjusted according to the patient’s clinical
situation. If the patient became excessively atropinized the
infusion was discontinued. If the patient developed further
cholinergic features further boluses (e.g., 10–15 mg IV) were
given.
Pralidoxime was administered 1 g q 6 h for 48 h as a slow IV
injection.
Clinical and Electrophysiological Assessment of Patients
All the patients were assessed at least twice daily with a
focused neurological examination to detect signs of IMS, and
at least six times a day for cholinergic signs. Bedside
electrophysiological testing was carried out using a portable
Medelec Synergy electromyography machine (software ver-
sion 11). The ﬁrst assessment was done within 24 h of
poisoning in 69 of 78 patients. The studies were repeated
daily until there were no detectable electrophysiological or
clinical abnormalities.
RNS was performed on right and left median and ulnar
nerves. Single supramaximal stimulation of the same nerves
was done to detect repetitive responses. Nerves were
stimulated superﬁcially by a stimulator ﬁxed to the respective
nerves at the wrist. Recordings were done with TECA NCS
disposable bar electrodes using the belly tendon conﬁgura-
tion. The ‘‘stimulation’’ hand was immobilized manually to
prevent movement artifacts. A 50-Hz notch ﬁlter was used.
RNS studies were done with train of ten supramaximal
stimuli of 0.1 ms at 1, 3, 10, 15, 20, and 30 Hz frequencies.
There was at least a 15 s interval between two trains of
stimuli.
To conﬁrm that motor conduction velocity was unaffected,
we measured this parameter in the ﬁrst 60 patients. Motor
conduction velocity was normal despite clinical weakness.
This conﬁrmed previous ﬁndings reported by others
[5,26,35,36] and we thus did not formally measure motor
conduction velocities in further patients.
A prospective deﬁnition for IMS was developed on the
basis of Senanayake and Karalliedde’s original description [5],
namely signiﬁcant muscle weakness in at least three of the
following muscle groups (extraocular, neck ﬂexor, proximal
limb, and facial) observed at least 24 h after ingestion of OP.
The weakness of proximal muscles and neck ﬂexion was
considered signiﬁcant when the muscle power was grade 3 or
less (Medical Research Council [MRC] grading): weakness of
respiratory muscles was not considered a requirement for the
diagnosis. While cholinergic features had usually subsided at
this time, short relapses of muscarinic signs or symptoms
would not exclude the diagnosis.
Data are presented with conventional nonparametric
descriptive summary statistics.
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Intermediate SyndromeResults
Of a total of 91 patients recruited, serial clinical and
electrophysiological assessments could be successfully com-
pleted in 78 (65 males). In 13 patients serial electrophysio-
logical studies were not successful (withdrawal of consent,
four; unable to perform due to restlessness/delirium, seven;
technical difﬁculties, two). The OP ingested was chlorpyrifos
in 59 of 78 patients. Two patients have ingested dime-
thoate:1 phenthoate:1 diazinon. In four patients, either the
OP was not detected (n ¼ 2), or the type of OP was not
conﬁrmed. Blood samples were not available or were not
assayed for OP levels in 11 patients. Depression of RBC
AChE to ,50% of the lower limit of the normal range and/or
toxicologically signiﬁcant concentrations of OP was detected
in 69 of 78.
IMS was diagnosed in nine of the 78 patients according to
our clinical diagnostic criteria. One additional patient
developed typical clinical features and characteristic electro-
physiological features of IMS 15 h after the ingestion during
the cholinergic crisis (increased secretions, pin point pupils,
diarrhea, and generalized fasciculations) despite atropine
therapy. She was intubated approximately 25 h postingestion
and was ventilated for 18 d. Late onset (.24 h) respiratory
failure requiring supported ventilation developed in ﬁve of
the ten IMS patients. Marked weakness of neck ﬂexion and
proximal limb muscles (MRC grade 3 or less) was the most
consistent feature in all ten patients. The most frequent
motor cranial nerve deﬁcits were facial muscle weakness (n ¼
10) and ptosis (n¼10). In addition, external ophthalmoparesis
was observed in one, and dysphagia in another. The onset of
muscle weakness varied from 15 h to 6 d. Deep tendon
reﬂexes were absent or depressed in six patients.
Of the ten IMS patients, two had both muscarinic features
and fasciculations at the time of diagnosis of IMS. One
patient had muscarinic features but no fasciculations, and
three of ten patients had fasciculations without any muscar-
inic signs at the time of diagnosis of IMS. Those who
developed respiratory failure took a longer time to recover
from the muscle weakness, whilst the others recovered within
24–48 h.
Pattern of RNS Abnormalities Observed in IMS Patients
In ﬁve of ten IMS patients (50%) the initial electro-
physiological changes were detected within the ﬁrst 24 h of
poisoning and in two patients within 24 and 48 h of
poisoning. The sequential changes were as outlined in the
following paragraphs.
Decrement-Increment Pattern
In this pattern, the maximum decrement was observed in
the second compound muscle action potential (CMAP). From
the third CMAP there was progressive recovery of the
amplitude until it attained the amplitude of the ﬁrst CMAP
typically by the fourth, ﬁfth, or sixth (Figures 1B and 2A, 20–
30 Hz). Decrement-increment initially occurred in high
frequency stimulations (20 and 30 Hz). As the patient
deteriorated clinically, the abnormalities occurred progres-
sively at intermediate frequencies (10 and 15 Hz) and then at
low frequencies (1 and 3 Hz). The decrement-increment seen
at high frequency stimulations changed to a combination of
decrement-increment and repetitive fade.
Combination of Decrement-Increment and Repetitive
Fade
Maximum decrement was seen at the second stimulus and
thereafter the amplitudes of the subsequent CMAP increased
but failed to attain the amplitude of the ﬁrst CMAP even at
the eight, ninth, or tenth (Figures 1C and 2B, 15–30 Hz) [24].
This pattern was initially seen only at high frequency
stimulations. As the muscular weakness progressed, the
change occurred at intermediate frequencies and there was
a corresponding decrement in the amplitude of the tenth
C M A P ,w h i c hw a sm o s tm a r k e dw i t hh i g hf r e q u e n c y
stimulations. Three of the ten IMS patients did not progress
beyond combination of decrement-increment and repetitive
fade electrophysiologically.
Severe Decrement Pattern
Here only a low amplitude ﬁrst CMAP was recordable, the
subsequent CMAPs being severely depressed or undetectable
(Figures 1D and 2C, 30 Hz). This pattern was typically seen at
30 Hz stimulations when patients showed maximal muscle
weakness (n¼7). Severe decrement pattern at high frequency
stimulations preceded respiratory failure in four patients.
When this pattern was seen at high frequency stimulations,
intermediate frequency stimulations usually demonstrated a
combination of decrement-increment and repetitive fade
phenomena, and at low frequency stimulations, decrement-
increment.
Progressive Decrement Pattern
The patients who developed respiratory failure with severe
muscle weakness developed progressive decrement following
a severe decrement (Figures 1E and 2D). As demonstrated in
Figure 2C and 2D, there was a transition of electrophysio-
logical features from severe decrement pattern to progressive
decrement pattern.
Figure 3 demonstrates how these changes look when
plotted longitudinally in a patient who developed respiratory
failure following IMS.
Patterns of RNS during the Recovery Stage of IMS
Recovery of RNS features was usually rapid and often
preceded clinical improvement in severe cases (see Figure 3
for very marked example of this phenomena). However, in a
few IMS patients who developed respiratory failure we
observed a particular pattern of RNS abnormalities during
recovery rather than a simple reversal of effects. The initial
changes during recovery were seen in lower and intermediate
frequency stimulations. The last to recover were the high
frequency response patterns. In the early recovery stages,
decrements were seen up to the fourth stimulus and then
there was little change from the ﬁfth to the tenth stimulus
(Figure 4A). Following this, a decrement was detected to
about the fourth stimulus and then slight increments from
the ﬁfth to the tenth stimulus (Figure 4B) Subsequently, the
pattern changed where the maximal decrement was observed
at the second CMAP followed by slight increments towards
the tenth stimulus (Figure 4C). The reduced amplitude of the
ﬁrst CMAP and subsequent depressed CMAPs reversed to
normal (Figure 1A) but with signiﬁcant interpatient variation.
Those patients who did not develop respiratory failure but
showed severe decrement or a combination of decrement-
increment and repetitive fade recovered earlier than those
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normalized within the next 24 h of the observation of
electrophysiological abnormalities.
Observation of a ‘‘forme fruste’’ IMS
A group of patients (30/78) developed varying degrees of
weakness, involving the neck ﬂexors, proximal limb muscles,
and muscles supplied by the motor cranial nerves, and
accompanied by characteristic electrophysiological abnor-
malities identical to early or intermediate stage changes that
were seen in IMS patients. We considered this a ‘‘forme fruste
IMS,’’ because they did not meet our study criteria for a
diagnosis of classical IMS.
Of these 30 patients ﬁve developed weakness of the neck
ﬂexors, proximal limb muscles, and cranial nerves but did not
meet predeﬁned criteria for a clinical diagnosis of IMS as they
had only mild (MRC grade 4) weakness. Three of the ﬁve
patients developed a combination of decrement-increment
and repetitive fade and two of ﬁve patients developed only
decrement-increment.
Twenty-ﬁve of 30 developed weakness of one or two of the
three muscle groups, but not all three. Of those, seven
patients developed decrement-increment and a combination
of decrement-increment and repetitive fade and 18 devel-
oped decrement-increments only. None of the 30 patients
who developed the forme fruste IMS showed severe decrement
on RNS.
Twenty-one of 30 (70%) developed electrophysiological
abnormalities within 48 h of ingestion of the poison. These
patients showed rapid clinical recovery, which was accom-
panied by normal electrophysiological recordings.
There were three of 78 patients who did not develop
clinically detectable muscle weakness but developed decre-
ment-increment at high frequency stimulations.
Those who were not diagnosed as IMS or forme fruste IMS,
did not develop decrement-increment patterns or severe
decrement patterns on serial RNS studies. They had normal
RNS and at high frequency stimulations pseudo-facilitation
was noted.
Figure 1. Electrophysiological Abnormalities during the Progression of IMS
(A) Normal response to train of ten stimuli.
(B) Decrement-increment pattern.
(C) Combination of decrement-increment and repetitive fade pattern.
(D) Severe decrement pattern.
(E) Progressive decrement pattern.
doi:10.1371/journal.pmed.0050147.g001
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Intermediate SyndromeFigure 2. Sequential RNS Changes in IMS
(A–C) Changes in amplitudes of the CMAPs over the train of ten stimuli at varying frequencies in a typical IMS patient (022/OP/NE) as he developed
progressively increasing weakness leading to respiratory failure.
(D) RNS abnormalities in a patient who was in respiratory failure (001/OP/PE) following severe muscle weakness.
(A) 20–30 Hz decrement-increment pattern; (B) 15–30 Hz combination of decrement-increment with repetitive fade; (C) 20–30 Hz severe decrement
pattern; (D) 10–30 Hz progressive decrement pattern.
Scale y-axis: 0–20 mV
doi:10.1371/journal.pmed.0050147.g002
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CMAP), and C10 (tenth CMAP) at 10Hz and 30Hz over
varying stages of the illness in the classical IMS and the forme
fruste IMS were seen to be different (Figure 5).
There was no difference in the treatment regimes between
those who developed IMS spectrum disorder and those who
did not. Both groups received 10–15 mg of a bolus dose of
intravenous atropine followed by 10–15 mg atropine infusion
over 12–24 h. The rate was adjusted according to the patients’
cholinergic status. Sixty-seven of 78 patients were treated
with pralidoxime 1g q 6 h for 48 h as per institutional
practice. Eleven (one IMS patient, six forme fruste IMS patients,
and four non-IMS patients) were not treated with pralidox-
ime as the drug was not available.
Refer to Table 1 for presenting disease severity, admission
characteristics, and the treatment details of IMS, forme fruste
IMS, and other patients.
Discussion
We found characteristic abnormalities on RNS associated
with the development and resolution of muscle weakness in
IMS. These clinical and electrophysiological changes varied in
severity, presumably representing a continuum through
which patients progress over time (Table 2).
The degree of muscle weakness correlated well with the
electrophysiological features during progression of IMS. The
only time there appeared to be a break in the continuum was
when the patients developed respiratory muscle weakness;
then there was a transition of the electrophysiological
features from decrement-increment and severe decrement
Figure 3. Comparison of RNS Changes with Neck Power
The progressive changes of amplitudes of C1 (first CMAP), C2 (second
CMAP), and C10 (tenth CMAP) at 10 Hz and 30 Hz over time in an IMS
patient (063/OP/NE) who subsequently developed respiratory failure.
Change of neck muscle power is also demonstrated.
doi:10.1371/journal.pmed.0050147.g003
Figure 4. Patterns of RNS during the Recovery Period of IMS
(A) RNS abnormalities seen during the early recovery stage, (B) RNS abnormalities seen during intermediate stage of recovery, and (C) RNS abnormalities
at the late recovery stage.
doi:10.1371/journal.pmed.0050147.g004
PLoS Medicine | www.plosmedicine.org July 2008 | Volume 5 | Issue 7 | e147 1148
Intermediate SyndromeFigure 5. Comparison of Average Amplitudes of C1, C2, and C10 between IMS and forme fruste Groups
The average amplitude of C1 (first CMAP), C2 (second CMAP), and C10 (tenth CMAP) in the Clinical IMS and forme fruste IMS at 10Hz and 30Hz
frequency. Changes are plotted for each day relative to day 0 (D0). D0 in the clinical IMS group is the day they were diagnosed as clinical IMS. The D0 in
forme fruste group is the day they were detected to have maximal muscle weakness.
doi:10.1371/journal.pmed.0050147.g005
Table 1. Presenting Disease Severity, Admission Characteristics, and the Treatment Details of IMS, forme fruste IMS, and Other Patients
Patient Information and Findings Parameters IMS FF IMS Non-IMS
n of patients — 10 33 35
Patient information Median age y (IQR) 26.5 (21.5–35) 29 (20–36) 24 (20–34.5)
Male gender % 7 (70%) 28 (84.8%) 30 (85.7%)
Admission findings Median GCS (IQR) 14 (9.5–15) 14 (11–15) 15 (11.5–15)
Median SBP mmHg (IQR) 120 (110–135) 120 (100–130) 120 (110–130)
Median pulse bpm (IQR) 80 (59–89) 64 (60–72) 68 (60–80)
Median time to admission min (IQR) 155 (71.5–450) 70 (32–232) 75 (52–270)
Frequency (%) ingested chlorpyrifos 6 (60%) 24 (72.7%) 29 (82.9%)
Frequency (%) received PAM 9 (90%) 27 (81.8%) 31 (88.6%)
Frequency (%) received atropine 10 (100%) 33 (100%) 35 (100%)
bpm, beats per minute; FF IMS, forme fruste IMS; GCS, Glasgow Coma Scale; IQR, interquartile range; PAM, pralidoxime; SBP, systolic blood pressure
doi:10.1371/journal.pmed.0050147.t001
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who fulﬁlled our a priori diagnostic criteria, suggesting that
these criteria are clinically useful in identifying patients at
risk of late respiratory failure.
Although the electrophysiological features closely parallel
the clinical severity during progression of IMS, the same was
not true during recovery. Electrophysiological changes some-
times improved long before the patient recovered normal
strength and respiratory efforts (Figure 3). This conﬁrms in a
much larger cohort, the observation reported by de Bleecker
in 1993 that the electromyography usually normalized before
the neurological symptoms [11]. However, in both these
studies only the distal muscles were measured, and these are
the least clinically affected in IMS. Phrenic nerve conduction
studies done by Singh et al. showed reduced CMAP amplitude
of diaphragmatic muscle correlated well with the need for
mechanical ventilation in OP poisoned patients. Further,
normalization of the diaphragmatic CMAP amplitudes was
noted in patients who could be successfully weaned, and
persistent or rebound abnormalities in those who failed a
trial of ventilatory discontinuation [26].
Some of these electrophysiological features have been
described earlier [8,22–26,35,37]. Animal studies have been
done to assess the nature of the neuromuscular transmission
failure that occurs following anticholinesterase/OP poisoning.
In 1991 Maselli et al. studied rats injected with diisopropyl-
ﬂuorophosphate (DFP). They noted decrement-increment
that was accentuated at high frequency stimulations. Edro-
phonium accentuated the decrement response; in contrast D-
tubocurarine corrected the electrophysiological decrement
[23]. In 1992 Besser et al. studied left phrenic hemi-
diaphragm preparations from rats. AChE was inhibited by a
transient perfusion of the hemi-diaphragm with neostigmine.
They observed decrement-increment and in some trains the
second CMAP was abolished without subsequent recovery by
the ninth stimulus [31]. This is similar to the severe
decrements we observed in OP-poisoned patients who had
severe muscle weakness. De Bleecker et al. studied rats
poisoned with paraoxon and fenthion (800 mg/kg subcuta-
neous). At high frequency stimulations they observed the two
types of decrements (decrement-increment phenomena and
decrement phenomena). The decrement-increment phenom-
enon preceded the decrement phenomenon and was asso-
ciated with slightly less severe AChE inhibition than
decrement [28].
This is the largest prospective cohort study evaluating the
electrophysiological abnormalities in IMS and the ﬁrst study
that has evaluated patients with serial RNS from the onset of
poisoning to describe sequential electrophysiological changes
that correlate with progression of the clinical severity in IMS.
An advantage of this study is the inclusion of a group of
symptomatic OP poisoned patients who did not demonstrate
electrophysiological evidence of neuromuscular transmission
failure.
These ﬁndings clearly demonstrate that IMS is a spectrum
disorder. At one end of the spectrum the patients demon-
strate only the electrophysiological abnormalities without
clinically detectable muscle weakness, and at the other end,
patients progress to severe muscular weakness with deterio-
ration of electrophysiological measurements and the risk of
respiratory failure. While our a priori diagnostic criteria
restricted a diagnosis of IMS to patients with MRC weakness
of grade 3 or less, this did identify a subgroup with worse
prognosis. Typical RNS ﬁndings in the forme fruste group
suggest that weakness of greater than MRC grade 3 in neck
ﬂexors and proximal limb muscles with or without weakness
of muscles supplied by the motor cranial nerves is clinically
useful as it reveals a much higher incidence of IMS than that
is usually described. Further we propose objective criteria for
the diagnosis of the stage of the IMS spectrum disorder on
the basis of our clinical and electrophysiological observations
(Table 2). These criteria need to be validated in future
prospective studies, however if adopted, they may reduce the
equivocation caused by the widespread nonspeciﬁc use of the
term IMS.
The original description of IMS states that it occurs
distinctly separate from the cholinergic syndrome. However
in the present study one patient was acutely cholinergic while
being diagnosed as IMS and some had short relapses of
muscarinic signs at the diagnosis of IMS. The electrophysio-
logical proﬁles of these patients were not different from the
others without overt muscarinic signs. This conﬁrms what was
observed previously by De Bleecker et al. in 1993 [11].
Oximes may potentially affect on the development of IMS
[12,38,39]. Addressing this issue is beyond the scope of this
study, as only a few patients did not receive pralidoxime and
our patients only received intermittent low dose pralidoxime
for approximately 48 h. However, there is a need for further
prospective studies with serial electrophysiological monitor-
Table 2. Proposed Criteria for Intermediate Spectrum Disorder Diagnosis
Muscle Weakness Electrophysiological Abnormality Proposed IMS Spectrum Diagnostic Term
None None None
None Decrement-increment at high frequencies Forme fruste IMS, stage I
Mild Decrement-increment at intermediate and high frequencies Forme fruste IMS, stage II
Moderate to severe Decrement-increment Forme fruste, IMS, stage III
Moderate to severe A combination of decrement-increment and repetitive fade
a Forme fruste IMS, stage IV
b
Moderate to severe Severe decrement
a IMS
Severe with respiratory failure Severe decrements followed by progressive decrements
a IMS with respiratory failure
aWorst features were seen at high frequencies, other patterns often present at lower frequencies.
bThree out of ten patients with clinical IMS developed abnormalities only up to decrement-increment and repetitive fade phenomena. However these were also observed in ten other patients
with moderate to severe weakness but not meeting our a priori criteria for clinical IMS. Thus this appears to be best categorized on RNS criteria as the most severe form of forme fruste IMS.
doi:10.1371/journal.pmed.0050147.t002
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Intermediate Syndromeing to measure the effects of pralidoxime on the neuro-
muscular junction and the development of IMS.
The early detection of RNS changes in IMS suggests that
underlying mechanism or mechanisms occur early. The key
stage where neuromuscular junction transmission fails even
to support respiratory function coincides with an electro-
physiological transition. The change from decrement-incre-
ment/severe decrements to progressive decrement is a feature
that has not been described before, and it may point to a
speciﬁc pathological process at this time.
The transient depolarization of the end-plate receptor is
the main factor accounting for the failure of neuromuscular
transmission observed during the exposure of the rat neuro-
muscular junction to low concentration of acetylcholinester-
ase [23]. In this study forme fruste IMS patients and classical
IMS patients, exhibited the decrement-increment pattern
during early stage of intoxication. In classical IMS patients,
decrement-increment pattern worsened to severe decrement
pattern at high frequency stimulations. Thus it is possible that
at early stages or in less severe cases there is depolarization
block at the neuromuscular junction. Persistent accumulation
of acetylcholine at the neuromuscular junction may lead to
desensitization block as described by Maselli et al. in 1993
[30]. Desensitization is said to counteract the depolarization
block but in the presence of high concentrations of
anticholinesterase, desensitization intensiﬁes the blockade
and it becomes the dominant mechanism of neuromuscular
transmission failure. The transition of electrophysiological
abnormalities from severe decrement to progressive decre-
ment pattern observed in our study may represent the
transition between the two types of neuromuscular blockade.
It has also been suggested that the persistent accumulation of
ACh at the nicotinic receptor causes either down regulation
[40] or conformational change of the N-receptor [15]. That
could lead to a reduction of the number of functioning N-
receptors at the postsynaptic junction. Further the direct
effect of OP at the neuromuscular junction causing con-
formational change as suggested by Katz et al. [15] cannot be
ruled out. This would be one possible explanation for why
some OPs have been demonstrated in both animals and
humans to be associated with a much higher incidence of IMS
[28,33].
The electrophysiological ﬁndings in other common neuro-
muscular junction disorders suggest that, the electrophysio-
logical ﬁndings of the IMS spectrum disorder are unlikely to
represent a single simple pre- or postsynaptic defect.
Myasthenia gravis causes a reduced density of functioning
AChR at the postjunctional membrane [41]. The character-
istic response to RNS at 2 to 3 Hz stimulation rate in
myasthenia gravis is a progressive decrement in amplitude of
the CMAP, which is most reliably found in weak muscles [42].
In Lambert-Eaton syndrome, there is a presynaptic neuronal
conduction block. Low amplitude CMAPs are seen on motor
nerve stimulation with marked facilitation of CMAP ampli-
tude after brief muscle contraction or following high-
frequency (20–50 Hz) RNS [43,44]. In botulism there is
enzymatic cleavage of proteins that are needed for the
exocytosis of ACh. As a result, ACh cannot be released and
the muscle is paralyzed [45]. The most consistent electro-
physiological abnormality is a small evoked muscle action
potential in response to a single supramaximal nerve stimulus
in a clinically affected muscle. A decrement response to RNS
at slow rates (2–3 Hz) is also occasionally seen [45]. Congenital
end-plate acetylcholinesterase deﬁciency produces decre-
ment patterns in RNS studies. Kohara et al. reported a case
in which they have noticed decrement-increment pattern at
20 Hz stimulation in mildly affected muscle [46]. However,
the cause of weakness and RNS ﬁndings in this rare condition
are not well understood but postulated to be explained by
both presynaptic (e.g., decreased choline substrate for ACh
production, negative feedback, damage to nerve terminal)
and postsynaptic (e.g., end-plate damage or persistent partial
depolarization, receptor desensitization) responses to persis-
tently high levels of ACh [47].
It seems likely that the pathogenesis of IMS in man is
complex. The toxicokinetics and dynamics of each speciﬁc
OP and the treatment the patient receives may inﬂuence
whether or not the condition develops. Inadequate treatment
with oximes may play a role, especially with di-ethyl OP that
should respond well [33]. It is also possible that there may be a
genetic susceptibility with some patients having altered ACh
pathways at the neuromuscular junction and postsynaptic
nicotinic receptor polymorphisms. Animal models of IMS
would be helpful to fully explore each of these potential
sources of variability.
Our electrophysiological ﬁndings could be used for
objective clinical assessments in the management of patients
following OP poisoning and in research (such as evaluating
effects of therapeutic agents or therapeutic regimen) once
they are validated in future prospective studies. Sequential
RNS need to be carried out to detect the development of the
severe decrement pattern, an ominous sign indicating that
respiratory failure is imminent. Less severe but evolving
abnormalities may indicate the need for longer observation
or transfer to higher level of care.
Conclusions
Our ﬁndings suggest that IMS is a spectrum disorder in
which the initial pathological process starts with acute
cholinergic state, which may or may not progress through a
series of electrophysiological changes leading to respiratory
failure and progressive decrement on RNS. Evolving electro-
physiological ﬁndings provide valuable new objective infor-
mation to facilitate assessments and to predict the
development of IMS. While these need to be validated in
future prospective studies, this study also provides objective
clinical/electrophysiological criteria for different stages of the
IMS spectrum. It is intended that these ﬁndings will stimulate
further clinical studies to determine the pathogenesis of IMS,
which may in turn help to improve the management of OP
poisoning.
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Background. Each year, many thousands of deaths around the world are
caused by pesticide poisoning. Often, the pesticide involved is an
organophosphate. These highly toxic compounds, which are widely used
in agriculture, particularly in developing countries, disrupt the trans-
mission of messages from the brain to the body in insect pests and in
people. The brain controls body movements by sending electrical
impulses along nerve cells (neurons). At the end of the neurons, these
impulses are converted into chemical messengers (neurotransmitters),
which cross the gap between neurons and muscle cells (the neuro-
muscular junction) and bind to proteins on the surface of the muscle
cells to pass on the brain’s message. One important neurotransmitter is
acetylcholine. This is used in the part of the nervous system that controls
breathing and other automatic vital functions, at neuromuscular
junctions, and in parts of the central nervous system. Normally,
acetylcholine is quickly broken down after it has delivered its message,
but organophosphates disrupt this process and, consequently, affect
nerve transmission to muscles. Organophosphate poisoning causes three
syndromes. The cholinergic syndrome, which can be fatal, happens soon
after organophosphates are swallowed, inhaled, or absorbed through
the skin. The intermediate syndrome (IMS), which results in muscle
weakness in the limbs, neck, and throat, develops in some patients 24–
96 hours after poisoning. Finally, long-term nerve damage sometimes
develops 2–3 weeks after poisoning.
Why Was This Study Done? Although IMS is a major contributor to the
illness caused by organophosphate poisoning and can result in
respiratory (breathing) failure and death, the functional changes that
are associated with IMS (its pathophysiology) are poorly understood.
With a better understanding of these changes, it might be possible to
find ways to prevent or treat IMS or to predict which patients with IMS
are likely to develop respiratory failure. In this study, the researchers
make a set of measurements of nerve transmission in a large group of
organophosphate-poisoned patients in Sri Lanka to discover more about
the pathophysiology of IMS.
What Did the Researchers Do and Find? Seventy-eight patients with
organophosphate poisoning were assessed several times a day for
clinical signs of IMS. In addition, nerve transmission was measured daily
in the patients using an electrophysiological technique called repetitive
nerve stimulation (RNS). For this, a series of small electrical shocks was
applied to the certain nerves in the arm and the responses in the muscles
that these nerves control were recorded. In the ten study participants
who developed IMS, the researchers observed several characteristic
changes in their muscle responses to RNS, some of which were seen
before the clinical signs of IMS. Other changes in muscle responses to
RNS correlated with the development of clear IMS. Most importantly, in
the four patients with IMS who developed respiratory failure, an RNS
response pattern called severe decrement (a reduced response to the
first electrical shock and then no response to the subsequent shocks)
was seen before respiratory failure. Finally, there were other character-
istic changes in muscle responses to RNS in 30 patients with muscle
weakness not severe enough for a diagnosis of IMS (incomplete or
‘‘forme fruste’’ IMS).
What Do These Findings Mean? These findings indicate that changes in
nerve transmission that can be objectively monitored using RNS evolve
during the development of IMS. In other words, IMS is a ‘‘spectrum’’
disorder in which the weakness and neuromuscular junction problems
caused by organophosphate poisoning gradually progress over time
through a series of electrophysiological changes that will sometimes
resolve quickly and only in the most severe cases will result in respiratory
failure. These findings need to be validated in further studies, particularly
since most of the patients in this study had been exposed to a single
organophosphate (chlorpyrifos). However, they suggest that the RNS
tests might be useful in the clinical management of patients with
organophosphate poisoning, particularly since such tests could provide
an early warning of impending respiratory failure.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050147.
  This study is further discussed in a PLoS Medicine Perspective by
Cynthia Aaron
  The US Environmental Protection Agency provides information about
all aspects of pesticides (in English and Spanish)
  Toxtown, an interactive site from the US National Library of Science,
provides information on environmental health concerns including
exposure to pesticides (in English and Spanish)
  The US National Pesticide Information Center provides objective,
science-based information about pesticides
  MedlinePlus also provides links to information on pesticides (in English
and Spanish)
  The International Programme on Chemical Safety has information on
poisoning prevention and management; its INTOX databank has a
description of the cholinergic syndrome
  WikiTox is a clinical toxicology resource
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